Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Glomerulonephritis Market?

The market size for glomerulonephritis has been experiencing consistent growth in the recent past. It’s predicted to increment from $11.06 billion in 2024 to $11.61 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be traced back to a surge in kidney diseases, the occurrence of infections like post-streptococcal glomerulonephritis, advancements in research and development, a rise in kidney failure cases, and an increased awareness about kidney-related health issues.

A consistent expansion is anticipated in the glomerulonephritis market in the coming years, reaching a size of $14.03 billion by 2029, with a compound annual growth rate (CAGR) of 4.9%. Factors contributing to the growth throughout the projected period comprise the rise in diabetes occurrences, a growing elderly population, amplified healthcare investments, a surge in dialysis patient numbers, and an increase in autoimmune diseases. Meanwhile, the period’s key trends are expected to be the introduction of fresh treatments and therapies, advancements in diagnostic tools, the emergence of innovative therapeutics, partnerships between corporations, and the rise of intravenous immunoglobulin therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

Which Industry Forces Are Driving The Glomerulonephritis Market Forward?

The increasing incidence of kidney-related illnesses is anticipated to boost the glomerulonephritis market’s expansion in the future. Kidney ailments encompass a variety of conditions that hinder the structural integrity or function of the kidneys, adversely affecting filtration, waste elimination, and fluid regulation. This escalating trend in kidney diseases can be attributed to an aging population, growing instances of chronic conditions like diabetes and hypertension, and lifestyle habits. The onset of disorders in the kidney can stimulate the occurrence of glomerulonephritis by causing the immune system to malfunction, chronic inflammation, or structural harm, culminating in disrupted kidney filtration and operation. For example, in December 2024, as per the Australian Institute of Health and Welfare, a governmental organization based in Australia, the death rate from chronic kidney disease (CKD) surged by 4.2% in 2021 and 6.2% in 2022. During 2021–22, approximately 2 million hospital admissions were attributed to CKD, accounting for 18% of nationwide hospital admissions. As a result, the escalating incidence of kidney diseases is projected to fuel the growth in the glomerulonephritis market.

How Is The Glomerulonephritis Market Organized By Different Segments?

The glomerulonephritismarket covered in this report is segmented –

1) By Type: Acute Glomerulonephritis; Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests; Imaging Tests; Kidney Biopsy; Other Diagnosis

3) By Treatment: Medication; Surgery; Dialysis; Other Treatments

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Specialty Clinics; Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis; IgA Nephropathy; Lupus Nephritis; Rapidly Progressive Glomerulonephritis (RPGN); Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS); Membranous Nephropathy; Minimal Change Disease; Alport Syndrome; Diabetic Nephropathy; Hypertensive Nephrosclerosis

What Current And Upcoming Trends Are Shaping The Glomerulonephritis Market?

In the glomerulonephritis market, top pharmaceutical companies are focusing on non-immunosuppressive treatment options to meet unmet medical needs and improve patient care. These therapies aim to treat diseases without impairing immune function. In September 2024, U.S.-based Travere Therapeutics Inc. introduced FILSPARI (sparsentan), an FDA-approved drug for treating IgA nephropathy—a common form of primary glomerulonephritis. FILSPARI is the first non-immunosuppressive treatment proven to significantly slow kidney function decline, representing a major advancement for patients with limited previous treatment options.

Who Are The Primary Market Leaders In The Glomerulonephritis Market?

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

How Do Regional Dynamics Influence The Glomerulonephritis Market Performance?

North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

Browse Through More Reports Similar to the Global Glomerulonephritis Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Hospital Acquired Infections Testing Kits Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model